Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

被引：22

作者：

Cortellini, Alessio ^{[1
,2
]}

Cannita, Katia ^{[3
]}

Tiseo, Marcello ^{[4
,5
]}

Cortinovis, Diego L. ^{[6
]}

Aerts, Joachim G. J., V ^{[7
]}

Baldessari, Cinzia ^{[8
]}

Giusti, Raffaele ^{[9
]}

Ferrara, Miriam G. ^{[10
,11
]}

D'Argento, Ettore ^{[10
]}

Grossi, Francesco ^{[12
]}

Guida, Annalisa ^{[13
]}

Berardi, Rossana ^{[14
]}

Morabito, Alessandro ^{[15
]}

Genova, Carlo ^{[16
]}

Antonuzzo, Lorenzo ^{[17
]}

Mazzoni, Francesca ^{[17
]}

De Toma, Alessandro ^{[18
]}

Signorelli, Diego ^{[18
,19
]}

Gelibter, Alain ^{[20
]}

Targato, Giada ^{[21
]}

Rastelli, Francesca ^{[22
]}

Chiari, Rita ^{[23
]}

Rocco, Danilo ^{[24
]}

Gori, Stefania ^{[25
]}

De Tursi, Michele ^{[26
]}

Mansueto, Giovanni ^{[27
]}

Zoratto, Federica ^{[28
]}

Filetti, Marco ^{[9
]}

Bracarda, Sergio ^{[29
]}

Citarella, Fabrizio ^{[30
]}

Russano, Marco ^{[30
]}

Cantini, Luca ^{[7
,14
]}

Nigro, Olga ^{[31
]}

Buti, Sebastiano ^{[5
]}

Minuti, Gabriele ^{[32
]}

Landi, Lorenza ^{[32
]}

Ricciardi, Serena ^{[33
]}

Migliorino, Maria R. ^{[33
]}

Natalizio, Salvatore ^{[34
]}

Simona, Carnio ^{[35
]}

De Filippis, Marco ^{[35
]}

Metro, Giulio ^{[36
]}

Adamo, Vincenzo ^{[37
]}

Russo, Alessandro ^{[37
]}

Spinelli, Gian P. ^{[38
]}

Di Maio, Massimo ^{[39
,40
]}

Banna, Giuseppe L. ^{[41
]}

Friedlaender, Alex ^{[42
]}

Addeo, Alfredo ^{[42
]}

Pinato, David J. ^{[2
,43
]}

机构：

[1] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England

[3] St Salvatore Hosp, Med Oncol, Laquila, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Osped San Gerardo, Med Oncol, Monza, Italy

[7] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands

[8] AOU Policlin Modena, Dipartimeto Oncol Ematol, Modena, Italy

[9] St Andrea Hosp, Med Oncolgy, Rome, Italy

[10] Fdn Policlin Univ Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Romae, Lazio, Italy

[12] Fdn IRCCS CaGranda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[13] Azienda Osped Santa Maria, Dept Oncol, Terni, Italy

[14] Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy

[15] Ist Nazl Tumori, IRCCS, Thorac Med Oncol, Fdn G Pascale, Naples, Italy

[16] Osped Policlin San Martino, Lung Canc Unit, IRCCS, Genoa, Italy

[17] Careggi Univ Hosp, Dept Oncol, Florence, Italy

[18] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy

[19] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[20] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[21] Univ Hosp Santa Maria Misericordia, Dept Oncol, Udine, Italy

[22] Med Oncol, Fermo Area Vasta 4, Fermo, Italy

[23] Osped Riuniti Padova Sud Madre Teresa Calcutta, Med Oncol, Monselice, Italy

[24] Monaldi Hosp, Pneumo Oncol Unit, Naples, Italy

[25] Osped Sacro Cuore Don Calabria, IRCCS, Oncol Unit, Negrar, VR, Italy

[26] Oral & Biotechnol Sci Univ G DAnnunzio, Dept Med, Chieti, Italy

[27] Spaziani Hosp, Med Oncol, Frosinone, Italy

[28] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[29] Azienda Osped Santa Maria Terni, Struttura Complessa Oncol Med & Traslaz, Terni, Italy

[30] Campus Biomed Univ, Med Oncol, Rome, Italy

[31] ASST Sette Laghi, Med Oncol, Varese, Italy

[32] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[33] St Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[34] Univ Modena & Raggio Emilia, Dipartimento Oncol Ematol, Modena, Italy

[35] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, TO, Italy

[36] Azienda Osped Perugia, Dept Med Oncol, Santa Maria Misericordia Hosp, Perugia, Italy

[37] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[38] Univ Rome Sapienza, UOC Terr Oncol Aprilia, AUSL Latina, Aprilia, Italy

[39] Univ Turin, Dept Oncol, Turin, Italy

[40] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[41] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[42] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[43] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 148卷

关键词：

Non-small cell lung cancer; Immunotherapy; PD-L1; Pembrolizumab; Performance status; Post-progression; Radiotherapy; Radiation therapy; CELL LUNG-CANCER; IMMUNE-CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; IMMUNOTHERAPY; RADIOTHERAPY; ASSOCIATION; ASSAYS;

D O I：

10.1016/j.ejca.2021.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression >50%. Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab monotherapy. Results: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95% CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). Conclusions: In the real-world scenario NSCLC patients with PD-L1 expression >50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页码：24 / 35

页数：12

共 50 条

[41] Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
E. Pons-Tostivint
P. Hulo
V. Guardiolle
L. Bodot
A. Rabeau
M. Porte
S. Hiret
P. Demontrond
H. Curcio
A. Boudoussier
R. Veillon
M. Mayenga
C. Dumenil
T. Chatellier
P. A. Gourraud
J. Mazieres
J. Bennouna
Cancer Immunology, Immunotherapy, 2023, 72 : 1891 - 1892
[42] PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
Lo Russo, Giuseppe
Ganzinelli, Monica
Sgambelluri, Francesco
Galli, Francesca
Prelaj, Arsela
Manglaviti, Sara
Bottiglieri, Achille
Di Mauro, Rosa Maria
Ferrara, Roberto
Dumitrascu, Andra Diana
Sottotetti, Elisa
Martinetti, Antonia
Fabbri, Alessandra
Rulli, Eliana
De Braud, Filippo G.
Torri, Valter
Garassino, Marina Chiara
Anichini, Andrea
Proto, Claudia
Mortarini, Roberta
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[43] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
Kuzminin, A.
Minatta, N.
Bluthgen, M.
Rizzo, M.
Naveira, M.
Wainsztein, V.
Lupinacci, L.
Rizzi, M.
Faura, M.
Perfetti, A.
Recondo, G., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
[44] The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Tamiya, M.
Tamiya, A.
Hosoya, K.
Taniguchi, Y.
Yokoyama, T.
Fukuda, Y.
Hirano, K.
Matsumoto, H.
Kominami, R.
Suzuki, H.
Hirashima, T.
Uchida, J.
Morita, M.
Kanazu, M.
Sawa, N.
Hara, S.
Kinoshita, Y.
Kumagai, T.
Fujimoto, D.
ANNALS OF ONCOLOGY, 2019, 30
[45] Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Cortellini, Alessio
Ricciuti, Biagio
Tiseo, Marcello
Bria, Emilio
Banna, Giuseppe L.
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Cortinovis, Diego L.
Migliorino, Maria R.
Catino, Annamaria
Passiglia, Francesco
Torniai, Mariangela
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Gelibter, Alain
Occhipinti, Mario Alberto
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Inno, Alessandro
De Tursi, Michele
Di Marino, Pietro
Mansueto, Giovanni
Zoratto, Federica
Grossi, Francesco
Filetti, Marco
Pizzutilo, Pamela
Russano, Marco
Citarella, Fabrizio
Cantini, Luca
Targato, Giada
Nigro, Olga
Ferrara, Miriam G.
Buti, Sebastiano
Scodes, Simona
Landi, Lorenza
Guaitoli, Giorgia
Della Gravara, Luigi
Tabbo, Fabrizio
Ricciardi, Serena
De Toma, Alessandro
Friedlaender, Alex
Petrelli, Fausto
Addeo, Alfredo
Porzio, Giampiero
Ficorella, Corrado
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[46] Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
Tambo, Yuichi
Sone, Takashi
Shibata, Kazuhiko
Nishi, Kouichi
Shirasaki, Hiroki
Yoneda, Taro
Araya, Tomoyuki
Kase, Kazumasa
Nishikawa, Shingo
Kimura, Hideharu
Kasahara, Kazuo
ANNALS OF ONCOLOGY, 2021, 32 : S313 - S313
[47] Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France
Perol, M.
Quantin, X.
Lena, H.
Filleron, T.
Chouaid, C.
Valette, C. Audigier
Kaderbhai, C.
Chenuc, G.
Santorelli, M.
Bensimon, L.
Burke, T.
Simon, G.
Martin, A-L.
Debieuvre, D.
Gervais, R.
Schott, R.
Carton, M.
Courtinard, C.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S758
[48] Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features
Passaro, A.
Giannarelli, D.
Bria, E.
Novello, S.
Galetta, D.
Gelibter, A. J.
Reale, M. L.
Carnio, S.
Vita, E.
Stefani, A.
Pizzutilo, P.
Stati, V.
Attili, I.
de Marinis, F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S754 - S755
[49] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
Ou Yamaguchi
Kyoichi Kaira
Kosuke Hashimoto
Atsuto Mouri
Ayako Shiono
Yu Miura
Yoshitake Murayama
Kunihiko Kobayashi
Hiroshi Kagamu
Ichiei Kuji
Scientific Reports, 10
[50] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
Yamaguchi, Ou
Kaira, Kyoichi
Hashimoto, Kosuke
Mouri, Atsuto
Shiono, Ayako
Miura, Yu
Murayama, Yoshitake
Kobayashi, Kunihiko
Kagamu, Hiroshi
Kuji, Ichiei
SCIENTIFIC REPORTS, 2020, 10 (01)

← 1 2 3 4 5 →

Post-progression outcomes of NSCLC patients with PD-L1 expression &gt; 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study